These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32042194)

  • 1. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
    Painter CA; Jain E; Tomson BN; Dunphy M; Stoddard RE; Thomas BS; Damon AL; Shah S; Kim D; Gómez Tejeda Zañudo J; Hornick JL; Chen YL; Merriam P; Raut CP; Demetri GD; Van Tine BA; Lander ES; Golub TR; Wagle N
    Nat Med; 2020 Feb; 26(2):181-187. PubMed ID: 32042194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
    Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
    Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.
    Teruyama F; Kuno A; Murata Y; Nakagawa T; Shiba-Ishii A; Yuguchi S; Noguchi M
    Pathol Int; 2022 Sep; 72(9):457-463. PubMed ID: 35801418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
    Beca F; Krings G; Chen YY; Hosfield EM; Vohra P; Sibley RK; Troxell ML; West RB; Allison KH; Bean GR
    Mod Pathol; 2020 Aug; 33(8):1518-1526. PubMed ID: 32123305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
    Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.
    Zhrebker L; Cherni I; Gross LM; Hinshelwood MM; Reese M; Aldrich J; Guileyardo JM; Roberts WC; Craig D; Von Hoff DD; Mennel RG; Carpten JD
    BMC Cancer; 2017 Jan; 17(1):17. PubMed ID: 28056866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma.
    Wan H; Zhang D; Hu W; Xie Z; Du Q; Xia Q; Wen T; Jia H
    Medicine (Baltimore); 2021 Jul; 100(30):e26779. PubMed ID: 34397726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Analysis of Renal/Adrenal Angiosarcomas Reveals High Frequency of Recurrent Genetic Alterations.
    Argani P; Saoud C; Antonescu CR
    Genes Chromosomes Cancer; 2024 Sep; 63(9):e23268. PubMed ID: 39248552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
    Boichard A; Wagner MJ; Kurzrock R
    Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
    Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
    Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
    Momen S; Fassihi H; Davies HR; Nikolaou C; Degasperi A; Stefanato CM; Dias JML; Dasgupta D; Craythorne E; Sarkany R; Papa S; Nik-Zainal S
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
    Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
    J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
    Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actionable mutations in canine hemangiosarcoma.
    Wang G; Wu M; Maloneyhuss MA; Wojcik J; Durham AC; Mason NJ; Roth DB
    PLoS One; 2017; 12(11):e0188667. PubMed ID: 29190660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma.
    Estabrooks T; Gurinovich A; Pietruska J; Lewis B; Harvey G; Post G; Lambert L; Miller A; Rodrigues L; White ME; Lopes C; London CA; Megquier K
    Vet Comp Oncol; 2023 Dec; 21(4):623-633. PubMed ID: 37734854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas.
    Calvete O; Garcia-Pavia P; Domínguez F; Mosteiro L; Pérez-Cabornero L; Cantalapiedra D; Zorio E; Ramón Y Cajal T; Crespo-Leiro MG; Teulé Á; Lázaro C; Morente MM; Urioste M; Benitez J
    J Am Heart Assoc; 2019 Sep; 8(18):e012875. PubMed ID: 31510873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure.
    Huang SC; Chang IY; Chang CJ; Liu H; Chen KH; Liu TT; Hsieh TY; Chuang HC; Chen CC; Lin IC; Ng KF; Huang HY; Chen TC
    J Pathol; 2023 Jun; 260(2):165-176. PubMed ID: 36815532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiative Suggests Angiosarcoma Therapies.
    Cancer Discov; 2020 Apr; 10(4):481-482. PubMed ID: 32122879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.
    Morris V; Rao X; Pickering C; Foo WC; Rashid A; Eterovic K; Kim T; Chen K; Wang J; Shaw K; Eng C
    Mol Cancer Res; 2017 Nov; 15(11):1542-1550. PubMed ID: 28784613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.